Evaluation of two buflomedil tablet formulations in patients with atherosclerotic disease

M. Molinaro, M. B. Regazzi, S. Raffaghello, I. Buggia, I. Iacona, P. Graziani, G. Specchia, G. M. D'Eril

Research output: Contribution to journalArticlepeer-review


The bioequivalence of a 600-mg methocel tablet containing buflomedil hydrochloride in sustained-release form was determined relative to a 300-mg CAP/carbovax-coated tablet of buflomedil hydrochloride in immediate-release form. The tablets were given to 20 patients in a double-blind placebo- controlled clinical study with cross-over between the administration plans. The 300-mg tablets were given b.i.d., at 8 a.m. and 8 p.m. while the 600-mg tablets were taken once a day at 8 a.m. (+placebo at 8 p.m.). Plasma samples were collected at appropriate times up to 24 h after administration and were analysed for buflomedil with a validated high-performance liquid chromatographic procedure. Results showed an overall significant mean difference in absorption rate between the two formulations. The mean t(max) (5.5 ± 3.5 h) for the 600-mg tablet was longer (P

Original languageEnglish
Pages (from-to)111-115
Number of pages5
JournalJournal of Clinical Pharmacy and Therapeutics
Issue number2
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Evaluation of two buflomedil tablet formulations in patients with atherosclerotic disease'. Together they form a unique fingerprint.

Cite this